Trials Sponsors Conditions Drugs Pricing

Conditions

Chronic Active Epstein-Barr Virus Infection Virus-Associated Hemophagocytic Syndrome

Outcome Measures

Primary Outcomes (1)

EBV-DNA
EBV-DNA negative conversion rate for patients with relapse/non-remission and EBV-DNA reactivation rate for high-risk patients
1 year

Study Arms (1)

EBV-CTL infusion patients

EXPERIMENTAL

Given donor EBV-CTL infusion after allo HSCT

Other: donor EBV-specific T lymphocytes

Interventions

donor EBV-specific T lymphocytesOther

EBV-DNA reactive after transplantation, or did not turn negative after +30 days, peripheral blood lymphocytes of the donor were collected to prepare EBV-CTL, and the first transfusion of EBV-CTL 6.0x105 was given at 48h to rapidly culture EBV-CTL, then EBV-CTL 6.0x105/kg was injected once a week untile EBV-DNA negative for 2 consecutive times or GVHD happened. After the second infusion, EBV-DNA did not decrease and there was no aGVHD patients, EBV-CTL infusion volume was increased to 1.2x106/kg, once a week. After 2 cycle infusion, EBV-DNA still did not decrease, and the reinfusion was terminated. Peripheral blood lymphocytes were collected from donors of high-risk patients at +14 days after allogeneic hematopoietic stem cell transplantation to prepare EBV-CTL, and EBV-CTL 6.0x105/kg was infused at +21d, +28d, +35d and + 42D for prevention. During treatment, if the patient develops GVHD, the infusion should be stopped.

EBV-CTL infusion patients

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

AgeUp to 65 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

Patients with CAEBV or EBV-HLH who were eligible for allogeneic hematopoietic stem cell transplantation agreed to regular monitoring of EBV-DNA after transplantation.
Age ≤65 years old, ECOG score 0-2.

Sponsors & Collaborators

Beijing Friendship Hospital
Otherlead

Study Sites (1)

Zhao Wang

Beijing, Beijing Municipality, 100050, China

RECRUITING

zhao wang, MDCONTACT8601063138303 wangzhao@ccmu.edu.cn

Study Officials

zhao wang, MD
Beijing Friendship Hospital
PRINCIPAL INVESTIGATOR

Central Study Contacts

zhao wang, MD

CONTACT

86010631383803 wangzhao@ccmu.edu.cn

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 6, 2022

First Posted

September 8, 2022

Study Start

October 8, 2022

Actual (reported)

Primary Completion

September 15, 2023

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Clinical Study of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-HLH After Allo-HSCT

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

EBV-CTL infusion patients

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

EBV-CTL infusion patients

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations